Leadership
Cyril Konto, M.D.
President, Executive Director and Chief Executive Officer
Cyril Konto is responsible for the overall management at IGI. He joined Ichnos as Chief Medical Officer and has served as the company’s Chief Executive Officer since May 2021. Previously, Cyril was Vice President of Clinical Development at Allogene Therapeutics, a spinoff from Pfizer, where he pioneered development of allogeneic CAR T-cell therapies.
At Pfizer, he was Executive Director of Early Immuno-oncology Clinical Development. Cyril began his industry career at Bristol Myers Squibb, first in medical affairs, and then in late-stage clinical development as clinical lead for the YERVOY® (ipilimumab) melanoma program. An oncologist by training, Cyril received his medical degree from University René Descartes in Paris and began practicing medicine at Pierre and Marie Curie University, where he held both clinical and academic positions.
Cyril Konto, M.D.
President, Executive Director and Chief Executive Officer
Cyril Konto is responsible for the overall management at IGI. He joined Ichnos as Chief Medical Officer and has served as the company’s Chief Executive Officer since May 2021. Previously, Cyril was Vice President of Clinical Development at Allogene Therapeutics, a spinoff from Pfizer, where he pioneered development of allogeneic CAR T-cell therapies.
At Pfizer, he was Executive Director of Early Immuno-oncology Clinical Development. Cyril began his industry career at Bristol Myers Squibb, first in medical affairs, and then in late-stage clinical development as clinical lead for the YERVOY® (ipilimumab) melanoma program. An oncologist by training, Cyril received his medical degree from University René Descartes in Paris and began practicing medicine at Pierre and Marie Curie University, where he held both clinical and academic positions.
Cyril Konto, M.D.
President, Executive Director and Chief Executive Officer
Cyril Konto is responsible for the overall management at IGI. He joined Ichnos as Chief Medical Officer and has served as the company’s Chief Executive Officer since May 2021. Previously, Cyril was Vice President of Clinical Development at Allogene Therapeutics, a spinoff from Pfizer, where he pioneered development of allogeneic CAR T-cell therapies.
At Pfizer, he was Executive Director of Early Immuno-oncology Clinical Development. Cyril began his industry career at Bristol Myers Squibb, first in medical affairs, and then in late-stage clinical development as clinical lead for the YERVOY® (ipilimumab) melanoma program. An oncologist by training, Cyril received his medical degree from University René Descartes in Paris and began practicing medicine at Pierre and Marie Curie University, where he held both clinical and academic positions.
Lida Pacaud, M.D.
Chief Medical Officer
Ichnos Glenmark Innovation
Lida Pacaud, M.D. is an accomplished physician and expert in oncology drug development. She has served as medical lead for clinical development strategies and execution of phase one to phase three programs. Lida has successfully delivered clearance of several Investigational New Drug applications for first-in-human CAR-T cell programs and has extensive experience with health authority interactions for marketing authorization submissions and approvals.
Prior to joining Ichnos, Lida served as Vice President, Head of Clinical Development and Medical Affairs at Legend Biotech where she led the Janssen J&J partnership for global development of CARVYKTI (BCMA CAR-T) and established the company’s clinical capabilities for early portfolio pipelines (except China territory).
She also previously worked on development of KYMRIAH (CD19 CAR-T) and AFINITOR (mTOR kinase inhibitor) at Novartis and AVASTIN (VEGF inhibitor mAb) at Hoffman la Roche.
Lida received her medical degree and a certification in pediatrics from Tbilisi State Medical University in Georgia and served as a clinical research physician and investigator at Robert-Debré Hospital in Paris.
Lida Pacaud, M.D.
Chief Medical Officer
Ichnos Glenmark Innovation
Lida Pacaud, M.D. is an accomplished physician and expert in oncology drug development. She has served as medical lead for clinical development strategies and execution of phase one to phase three programs. Lida has successfully delivered clearance of several Investigational New Drug applications for first-in-human CAR-T cell programs and has extensive experience with health authority interactions for marketing authorization submissions and approvals.
Prior to joining Ichnos, Lida served as Vice President, Head of Clinical Development and Medical Affairs at Legend Biotech where she led the Janssen J&J partnership for global development of CARVYKTI (BCMA CAR-T) and established the company’s clinical capabilities for early portfolio pipelines (except China territory).
She also previously worked on development of KYMRIAH (CD19 CAR-T) and AFINITOR (mTOR kinase inhibitor) at Novartis and AVASTIN (VEGF inhibitor mAb) at Hoffman la Roche.
Lida received her medical degree and a certification in pediatrics from Tbilisi State Medical University in Georgia and served as a clinical research physician and investigator at Robert-Debré Hospital in Paris.
Lida Pacaud, M.D.
Chief Medical Officer
Ichnos Glenmark Innovation
Lida Pacaud, M.D. is an accomplished physician and expert in oncology drug development. She has served as medical lead for clinical development strategies and execution of phase one to phase three programs. Lida has successfully delivered clearance of several Investigational New Drug applications for first-in-human CAR-T cell programs and has extensive experience with health authority interactions for marketing authorization submissions and approvals.
Prior to joining Ichnos, Lida served as Vice President, Head of Clinical Development and Medical Affairs at Legend Biotech where she led the Janssen J&J partnership for global development of CARVYKTI (BCMA CAR-T) and established the company’s clinical capabilities for early portfolio pipelines (except China territory).
She also previously worked on development of KYMRIAH (CD19 CAR-T) and AFINITOR (mTOR kinase inhibitor) at Novartis and AVASTIN (VEGF inhibitor mAb) at Hoffman la Roche.
Lida received her medical degree and a certification in pediatrics from Tbilisi State Medical University in Georgia and served as a clinical research physician and investigator at Robert-Debré Hospital in Paris.
Mario Perro, Ph.D.
Head of Biologics Research
Ichnos Glenmark Innovation
Mario Perro Ph.D. helms Biologics Research for Ichnos Glenmark Innovation. A biomedical scientist, he specializes in basic and translational cancer biology, cancer immunology, and immunology.
Mario joined Ichnos Sciences in 2021; heading the Oncology Department based out of Lausanne, Switzerland. He has played a key role in the development of next-generation immunotherapies based on the BEAT® platform. With over eleven years of expertise and a strong focus on understanding the activation, regulation, and genetic engineering of human and murine lymphocytes, Mario has made significant contributions utilizing molecular biology, preclinical models, and advanced imaging tools.
Formerly, Mario was Principal Scientist, Cancer Immunotherapy, Pharmacology Department at Roche Pharma. There, he was responsible for designing studies, managing experiments, analyzing results, and publishing preclinical exploratory investigations. His work contributed to defining the efficacy and mode of action of antibody-based cancer immunotherapies at both preclinical and clinical stages.
Mario has a Post-Doctoral Fellowship from Harvard Medical School, Immune Disease Institute in 2015, and holds a Ph.D. in Immunology, virology, oncology from University College London. He has been a Visiting Researcher at Harvard Medical College and a Research Assistant at the University of Turin.
Mario Perro, Ph.D.
Head of Biologics Research
Ichnos Glenmark Innovation
Mario Perro Ph.D. helms Biologics Research for Ichnos Glenmark Innovation. A biomedical scientist, he specializes in basic and translational cancer biology, cancer immunology, and immunology.
Mario joined Ichnos Sciences in 2021; heading the Oncology Department based out of Lausanne, Switzerland. He has played a key role in the development of next-generation immunotherapies based on the BEAT® platform. With over eleven years of expertise and a strong focus on understanding the activation, regulation, and genetic engineering of human and murine lymphocytes, Mario has made significant contributions utilizing molecular biology, preclinical models, and advanced imaging tools.
Formerly, Mario was Principal Scientist, Cancer Immunotherapy, Pharmacology Department at Roche Pharma. There, he was responsible for designing studies, managing experiments, analyzing results, and publishing preclinical exploratory investigations. His work contributed to defining the efficacy and mode of action of antibody-based cancer immunotherapies at both preclinical and clinical stages.
Mario has a Post-Doctoral Fellowship from Harvard Medical School, Immune Disease Institute in 2015, and holds a Ph.D. in Immunology, virology, oncology from University College London. He has been a Visiting Researcher at Harvard Medical College and a Research Assistant at the University of Turin.
Mario Perro, Ph.D.
Head of Biologics Research
Ichnos Glenmark Innovation
Mario Perro Ph.D. helms Biologics Research for Ichnos Glenmark Innovation. A biomedical scientist, he specializes in basic and translational cancer biology, cancer immunology, and immunology.
Mario joined Ichnos Sciences in 2021; heading the Oncology Department based out of Lausanne, Switzerland. He has played a key role in the development of next-generation immunotherapies based on the BEAT® platform. With over eleven years of expertise and a strong focus on understanding the activation, regulation, and genetic engineering of human and murine lymphocytes, Mario has made significant contributions utilizing molecular biology, preclinical models, and advanced imaging tools.
Formerly, Mario was Principal Scientist, Cancer Immunotherapy, Pharmacology Department at Roche Pharma. There, he was responsible for designing studies, managing experiments, analyzing results, and publishing preclinical exploratory investigations. His work contributed to defining the efficacy and mode of action of antibody-based cancer immunotherapies at both preclinical and clinical stages.
Mario has a Post-Doctoral Fellowship from Harvard Medical School, Immune Disease Institute in 2015, and holds a Ph.D. in Immunology, virology, oncology from University College London. He has been a Visiting Researcher at Harvard Medical College and a Research Assistant at the University of Turin.
Nagaraj Gowda, Ph.D.
Head of Small Molecule Research
Ichnos Glenmark Innovation
Nagaraj Gowda Ph.D. is an accomplished pharmaceutical professional with extensive experience in drug discovery. He brings to his role in IGI a wealth of expertise in cancer drug discovery for both tumor and immune targets. Nagaraj has been associated with Glenmark Pharmaceuticals Ltd. since 2018; where he headed the NCE Discovery Group in Mumbai. He led the teams involved in medicinal chemistry, biology, pharmacology and drug metabolism and pharmacokinetics (DMPK) research associated with small molecule drug discovery.
Prior to Glenmark, he was the Senior Group Lead for Immunology and Translational Biology at Aurigene Discovery Technologies working on immune-oncology, inflammatory and anti-infective projects.
Nagaraj is a Ph.D. in Biotechnology from National Chemical Laboratory, Pune. He was also a Senior Post-Doctoral Fellow from the John Hopkins School of Medicine as well a Post-Doctoral Scholar from the Hershey Medical Centre, Penn State University College of Medicine.
Nagaraj Gowda, Ph.D.
Head of Small Molecule Research
Ichnos Glenmark Innovation
Nagaraj Gowda Ph.D. is an accomplished pharmaceutical professional with extensive experience in drug discovery. He brings to his role in IGI a wealth of expertise in cancer drug discovery for both tumor and immune targets. Nagaraj has been associated with Glenmark Pharmaceuticals Ltd. since 2018; where he headed the NCE Discovery Group in Mumbai. He led the teams involved in medicinal chemistry, biology, pharmacology and drug metabolism and pharmacokinetics (DMPK) research associated with small molecule drug discovery.
Prior to Glenmark, he was the Senior Group Lead for Immunology and Translational Biology at Aurigene Discovery Technologies working on immune-oncology, inflammatory and anti-infective projects.
Nagaraj is a Ph.D. in Biotechnology from National Chemical Laboratory, Pune. He was also a Senior Post-Doctoral Fellow from the John Hopkins School of Medicine as well a Post-Doctoral Scholar from the Hershey Medical Centre, Penn State University College of Medicine.
Nagaraj Gowda, Ph.D.
Head of Small Molecule Research
Ichnos Glenmark Innovation
Nagaraj Gowda Ph.D. is an accomplished pharmaceutical professional with extensive experience in drug discovery. He brings to his role in IGI a wealth of expertise in cancer drug discovery for both tumor and immune targets. Nagaraj has been associated with Glenmark Pharmaceuticals Ltd. since 2018; where he headed the NCE Discovery Group in Mumbai. He led the teams involved in medicinal chemistry, biology, pharmacology and drug metabolism and pharmacokinetics (DMPK) research associated with small molecule drug discovery.
Prior to Glenmark, he was the Senior Group Lead for Immunology and Translational Biology at Aurigene Discovery Technologies working on immune-oncology, inflammatory and anti-infective projects.
Nagaraj is a Ph.D. in Biotechnology from National Chemical Laboratory, Pune. He was also a Senior Post-Doctoral Fellow from the John Hopkins School of Medicine as well a Post-Doctoral Scholar from the Hershey Medical Centre, Penn State University College of Medicine.
Dean Thomas
General Counsel
Ichnos Glenmark Innovation
Dean Thomas is an accomplished life sciences lawyer with an international career that spans both private practice and industry. With a diverse range of experience across various geographies and technical domains, Dean brings a unique blend of critical reasoning and creative problem-solving to the table. He excels in people management, leading diverse and dispersed teams with a personable and approachable management style.
Dean’s extensive career includes roles at prominent healthcare organizations such as Pfizer, Amgen, Glenmark Pharmaceuticals, and Ichnos Sciences, as well as law firms in the UK, USA, Germany, and France. He has successfully led legal and intellectual property teams to address complex issues affecting life sciences companies, particularly in multi-jurisdiction litigation and resolving intricate legal disputes. Dean has also played a pivotal role in orchestrating multiple product launches across the globe.
Dean Thomas
General Counsel
Ichnos Glenmark Innovation
Dean Thomas is an accomplished life sciences lawyer with an international career that spans both private practice and industry. With a diverse range of experience across various geographies and technical domains, Dean brings a unique blend of critical reasoning and creative problem-solving to the table. He excels in people management, leading diverse and dispersed teams with a personable and approachable management style.
Dean’s extensive career includes roles at prominent healthcare organizations such as Pfizer, Amgen, Glenmark Pharmaceuticals, and Ichnos Sciences, as well as law firms in the UK, USA, Germany, and France. He has successfully led legal and intellectual property teams to address complex issues affecting life sciences companies, particularly in multi-jurisdiction litigation and resolving intricate legal disputes. Dean has also played a pivotal role in orchestrating multiple product launches across the globe.
Dean Thomas
General Counsel
Ichnos Glenmark Innovation
Dean Thomas is an accomplished life sciences lawyer with an international career that spans both private practice and industry. With a diverse range of experience across various geographies and technical domains, Dean brings a unique blend of critical reasoning and creative problem-solving to the table. He excels in people management, leading diverse and dispersed teams with a personable and approachable management style.
Dean’s extensive career includes roles at prominent healthcare organizations such as Pfizer, Amgen, Glenmark Pharmaceuticals, and Ichnos Sciences, as well as law firms in the UK, USA, Germany, and France. He has successfully led legal and intellectual property teams to address complex issues affecting life sciences companies, particularly in multi-jurisdiction litigation and resolving intricate legal disputes. Dean has also played a pivotal role in orchestrating multiple product launches across the globe.
Sébastien Chenuet, Ph.D.
Sébastien C. is a distinguished professional heading the Business Development and Licensing at Ichnos Glenmark Innovation, Switzerland, as the Vice President since 2022. With a career spanning several prominent organizations, he has amassed a wealth of experience and expertise in the field of business development.
Prior to his current role at IGI, Sebastien held the position of Director of Business Development at Roche, a globally renowned pharmaceutical company. His responsibilities included spearheading strategic initiatives to drive business growth and enhance collaborations within the industry.
Sébastien’s career journey also includes significant contributions to Debiopharm International SA, where he demonstrated his commitment to excellence at various levels within the organization. His versatile background extends to notable roles at Cellectis, evitria SA, and a two-year stint with Glenmark Pharmaceuticals Limited, Switzerland, in 2007.
Sébastien C. holds a Ph.D. in Bioengineering and Biotechnology from Ecole polytechnique fédérale de Lausanne, showcasing his commitment to academic excellence. Additionally, he earned an Engineering Degree in Bioprocess Engineering and Biotechnology from ENSAIA, further solidifying his foundation in the biotechnology domain.
Sébastien C. is a seasoned professional with a robust background in business development and licensing within the pharmaceutical and biotechnology sectors. His extensive experience, coupled with a strong educational foundation, positions him as a valuable asset to any organization aiming for strategic growth and industry leadership. Sébastien’s current role as Vice President at Ichnos Sciences underscores his continued commitment to driving excellence and making impactful contributions to the field.
Sébastien Chenuet, Ph.D.
Sébastien C. is a distinguished professional heading the Business Development and Licensing at Ichnos Glenmark Innovation, Switzerland, as the Vice President since 2022. With a career spanning several prominent organizations, he has amassed a wealth of experience and expertise in the field of business development.
Prior to his current role at IGI, Sebastien held the position of Director of Business Development at Roche, a globally renowned pharmaceutical company. His responsibilities included spearheading strategic initiatives to drive business growth and enhance collaborations within the industry.
Sébastien’s career journey also includes significant contributions to Debiopharm International SA, where he demonstrated his commitment to excellence at various levels within the organization. His versatile background extends to notable roles at Cellectis, evitria SA, and a two-year stint with Glenmark Pharmaceuticals Limited, Switzerland, in 2007.
Sébastien C. holds a Ph.D. in Bioengineering and Biotechnology from Ecole polytechnique fédérale de Lausanne, showcasing his commitment to academic excellence. Additionally, he earned an Engineering Degree in Bioprocess Engineering and Biotechnology from ENSAIA, further solidifying his foundation in the biotechnology domain.
Sébastien C. is a seasoned professional with a robust background in business development and licensing within the pharmaceutical and biotechnology sectors. His extensive experience, coupled with a strong educational foundation, positions him as a valuable asset to any organization aiming for strategic growth and industry leadership. Sébastien’s current role as Vice President at Ichnos Sciences underscores his continued commitment to driving excellence and making impactful contributions to the field.
Sébastien Chenuet, Ph.D.
Sébastien C. is a distinguished professional heading the Business Development and Licensing at Ichnos Glenmark Innovation, Switzerland, as the Vice President since 2022. With a career spanning several prominent organizations, he has amassed a wealth of experience and expertise in the field of business development.
Prior to his current role at IGI, Sebastien held the position of Director of Business Development at Roche, a globally renowned pharmaceutical company. His responsibilities included spearheading strategic initiatives to drive business growth and enhance collaborations within the industry.
Sébastien’s career journey also includes significant contributions to Debiopharm International SA, where he demonstrated his commitment to excellence at various levels within the organization. His versatile background extends to notable roles at Cellectis, evitria SA, and a two-year stint with Glenmark Pharmaceuticals Limited, Switzerland, in 2007.
Sébastien C. holds a Ph.D. in Bioengineering and Biotechnology from Ecole polytechnique fédérale de Lausanne, showcasing his commitment to academic excellence. Additionally, he earned an Engineering Degree in Bioprocess Engineering and Biotechnology from ENSAIA, further solidifying his foundation in the biotechnology domain.
Sébastien C. is a seasoned professional with a robust background in business development and licensing within the pharmaceutical and biotechnology sectors. His extensive experience, coupled with a strong educational foundation, positions him as a valuable asset to any organization aiming for strategic growth and industry leadership. Sébastien’s current role as Vice President at Ichnos Sciences underscores his continued commitment to driving excellence and making impactful contributions to the field.
Eva Yuen
Head of Finance
Ichnos Glenmark Innovation
Eva Yuen
Head of Finance
Ichnos Glenmark Innovation
Eva Yuen
Head of Finance
Ichnos Glenmark Innovation
Karishma Sipahimalani, Ph.D.
Head of Human Resources
Ichnos Glenmark Innovation
Karishma Sipahimalani heads the Human Resources function at Ichnos Glenmark Innovation. Her experience extends to various facets of the pharmaceutical industry, currently focusing on talent acquisition and management for senior positions. She has also been the HR Business Partner for Innovative Medicines Group at Glenmark Pharmaceuticals Ltd.
Karishma is a Ph.D. in Biology / Biological Sciences from the University of California, Irvine and was also a Postdoctoral Research Associate at the University of Southern California. Her academic background includes a Master’s degree in Medical Genetics from the University of Glasgow, Scotland and a Bachelor’s degree in Life Sciences from St. Xavier’s College, Mumbai. Her diverse background in academia and industry positions her as a valuable asset in the biotech and pharmaceutical sectors.
Prior to joining Glenmark, Karishma served as a Principal Consultant at Vito India Advisors, where she was responsible for establishing and overseeing the pharmaceutical/life sciences and healthcare practice within the firm.
Karishma Sipahimalani, Ph.D.
Head of Human Resources
Ichnos Glenmark Innovation
Karishma Sipahimalani heads the Human Resources function at Ichnos Glenmark Innovation. Her experience extends to various facets of the pharmaceutical industry, currently focusing on talent acquisition and management for senior positions. She has also been the HR Business Partner for Innovative Medicines Group at Glenmark Pharmaceuticals Ltd.
Karishma is a Ph.D. in Biology / Biological Sciences from the University of California, Irvine and was also a Postdoctoral Research Associate at the University of Southern California. Her academic background includes a Master’s degree in Medical Genetics from the University of Glasgow, Scotland and a Bachelor’s degree in Life Sciences from St. Xavier’s College, Mumbai. Her diverse background in academia and industry positions her as a valuable asset in the biotech and pharmaceutical sectors.
Prior to joining Glenmark, Karishma served as a Principal Consultant at Vito India Advisors, where she was responsible for establishing and overseeing the pharmaceutical/life sciences and healthcare practice within the firm.
Karishma Sipahimalani, Ph.D.
Head of Human Resources
Ichnos Glenmark Innovation
Karishma Sipahimalani heads the Human Resources function at Ichnos Glenmark Innovation. Her experience extends to various facets of the pharmaceutical industry, currently focusing on talent acquisition and management for senior positions. She has also been the HR Business Partner for Innovative Medicines Group at Glenmark Pharmaceuticals Ltd.
Karishma is a Ph.D. in Biology / Biological Sciences from the University of California, Irvine and was also a Postdoctoral Research Associate at the University of Southern California. Her academic background includes a Master’s degree in Medical Genetics from the University of Glasgow, Scotland and a Bachelor’s degree in Life Sciences from St. Xavier’s College, Mumbai. Her diverse background in academia and industry positions her as a valuable asset in the biotech and pharmaceutical sectors.
Prior to joining Glenmark, Karishma served as a Principal Consultant at Vito India Advisors, where she was responsible for establishing and overseeing the pharmaceutical/life sciences and healthcare practice within the firm.
Edsel Pereira
Head of IT
Ichnos Glenmark Innovation
Edsel Pereira heads the Information Technology function at IGI and provides a critical interface between the business and IT functions. With a career spanning over thirty years, he joined Glenmark Pharmaceuticals Ltd. in 2012 and is responsible for implementing key business systems with a focus on compliance, driving business transformation, and process optimization globally. Edsel is accountable for enabling IT to implement key business systems of high criticality and compliance nuances and increased automation in the ever-increasing regulatory and compliance framework.
Recognized for his open management style and for fostering inclusiveness among in-house and outsourced teams, Edsel ensures data security and automation for the organization by adopting industry best practices and proven technologies.
Edsel has a Masters degree in Commerce from Mumbai University as well as in Management Science, majoring in Finance, from Pune University. Committed to continuous education and learning, he has also completed the Driving Digital Strategy program from Harvard Business School and holds multiple certifications in technology platforms. Edsel’s career is marked by numerous accomplishments and awards, demonstrating his impact on IT, digital strategy, and business management.
Edsel Pereira
Head of IT
Ichnos Glenmark Innovation
Edsel Pereira heads the Information Technology function at IGI and provides a critical interface between the business and IT functions. With a career spanning over thirty years, he joined Glenmark Pharmaceuticals Ltd. in 2012 and is responsible for implementing key business systems with a focus on compliance, driving business transformation, and process optimization globally. Edsel is accountable for enabling IT to implement key business systems of high criticality and compliance nuances and increased automation in the ever-increasing regulatory and compliance framework.
Recognized for his open management style and for fostering inclusiveness among in-house and outsourced teams, Edsel ensures data security and automation for the organization by adopting industry best practices and proven technologies.
Edsel has a Masters degree in Commerce from Mumbai University as well as in Management Science, majoring in Finance, from Pune University. Committed to continuous education and learning, he has also completed the Driving Digital Strategy program from Harvard Business School and holds multiple certifications in technology platforms. Edsel’s career is marked by numerous accomplishments and awards, demonstrating his impact on IT, digital strategy, and business management.
Edsel Pereira
Head of IT
Ichnos Glenmark Innovation
Edsel Pereira heads the Information Technology function at IGI and provides a critical interface between the business and IT functions. With a career spanning over thirty years, he joined Glenmark Pharmaceuticals Ltd. in 2012 and is responsible for implementing key business systems with a focus on compliance, driving business transformation, and process optimization globally. Edsel is accountable for enabling IT to implement key business systems of high criticality and compliance nuances and increased automation in the ever-increasing regulatory and compliance framework.
Recognized for his open management style and for fostering inclusiveness among in-house and outsourced teams, Edsel ensures data security and automation for the organization by adopting industry best practices and proven technologies.
Edsel has a Masters degree in Commerce from Mumbai University as well as in Management Science, majoring in Finance, from Pune University. Committed to continuous education and learning, he has also completed the Driving Digital Strategy program from Harvard Business School and holds multiple certifications in technology platforms. Edsel’s career is marked by numerous accomplishments and awards, demonstrating his impact on IT, digital strategy, and business management.